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In May 2019, 29 scientists with expertise in various subdisciplines of bioﬁlm research got together in Leavenworth (WA, USA) at an event designated as the ‘2019
Bioﬁlm Bash’. The goal of this informal two-day meeting was ﬁrst to identify gaps in our knowledge, and then to come up with ways how the bioﬁlm community can
ﬁll these gaps. The meeting was organized around six questions that covered the most important items brought forward by the organizers and participants. The
outcome of these discussions is summarized in the present paper. We are aware that these views represent a small subset of our ﬁeld, and that inevitably we will have
inadvertently overlooked important developing research areas and ideas. We are nevertheless hopeful that this report will stimulate discussions and help create new
ways of how we can advance our ﬁeld.Introduction
In October 2005 Bill Costerton invited a small group of established
and junior bioﬁlm researchers to a ‘Bioﬁlm Bash’ in Los Angeles (CA,
USA) to discuss the rapid advances that had developed in the ﬁeld over
the preceding decade, to think about how new and exciting technologies
could be applied to bioﬁlm research and to identify directions that the
ﬁeld might develop in the future. A decade later in 2015 discussions
started about having a second ‘Bioﬁlm Bash’ to again take stock of the
ﬁeld and discuss both old and new challenges as well as new opportu-
nities in bioﬁlm research and education; this second ‘Bioﬁlm Bash’
materialized in 2019.
From May 7 to 9, 2019, the Ponderosa Lodge in Leavenworth (WA,
USA) was the scene of this ‘2019 Bioﬁlm Bash’, organized by the late
Mark Shirtliff, Paul Stoodley, Birthe Kjellerup, Tom Coenye and Thomas
Bjarnsholt. The main goals were to identify the gaps in our bioﬁlm
knowledge, identify ways how we can ﬁll those gaps, and determine how
we can increase our impact related to bioﬁlms with various stakeholders.
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preceding months and years. The underlying thought that brought about
the ‘Bioﬁlm Bash’ was that the bioﬁlm community is scattered as a
subdiscipline within many other ﬁelds. For example, dental plaque,
activated sludge, oil ﬁeld souring, native valve endocarditis, respiratory
tract infections in cystic ﬁbrosis, microbial corrosion, indwelling medical
device infections, microbial fuel cells, endophthalmitis, osteomyelitis,
and prosthetic joint infections are all bioﬁlm-related – i.e. the mecha-
nisms behind them have many commonalities, yet we lack the unity that
can be found in other research topics (e.g. cancer).
An integral part of the meeting preparation included invitation of
participants that would reﬂect the overall diversity of the bioﬁlm ﬁeld
and at the same time created a balance between more established bioﬁlm
researchers and people that are new to the ﬁeld and/or come in from a
different angle. To allow fruitful participation, manageable and produc-
tive small group discussions (with max. six people in each group), and
because of logistical reasons, the target number of attendees was set at
approx. 30. Potential participants were identiﬁed in a decentralized way,
where Birthe Kjellerup, Darla Goeres, Kendra Rumbaugh, Matthewrsity, Ghent, Belgium.
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Table 1
Overview of participants and their afﬁliation.
Name Afﬁliation City, country
Nuno Azevedo University of Porto Porto, Portugal
Haluk Beyenal Washington State University Pullman, WA, USA
Thomas
Bjarnsholt
Costerton Bioﬁlm Center Copenhagen,
Denmark
Mette Burmølle University of Copenhagen Copenhagen,
Denmark
Tom Coenye Ghent University Ghent, Belgium
Vaughn Cooper University of Pittsburgh Pittsburgh, PA, USA
Matthew Fields Center for Bioﬁlm Engineering Bozeman, MT, USA
Darla Goeres Center for Bioﬁlm Engineering Bozeman, MT, USA
Luanne Hall-
Stoodley
The Ohio State University Columbus, OH, USA
Birthe V.
Kjellerup
University of Maryland College Park, MD,
USA
Michel Koo University of Pennsylvania Philadelphia, PA,
USA
Kasper Kragh Costerton Bioﬁlm Center Copenhagen,
Denmark
Bastiaan Krom Academic Centre for Dentistry Amsterdam, The
Netherlands
Tagbo Niepa University of Pittsburgh Pittsburgh, PA, USA
Matthew Parsek University of Washington Seattle, WA, USA
Gordon
Ramage
University of Glasgow Glasgow, UK
Courtney
Reichhardt
University of Washington Seattle, WA, USA
Alex Rickard University of Michigan Ann Arbor, MI, USA
Katharina
Richter
University of Adelaide Adelaide, Australia
Trine Rolighed
Thomsen
Aalborg University and Danish
Technological Institute
Aalborg and Aarhus,
Denmark
Kendra
Rumbaugh
Texas Tech University Health Sciences
Center
Lubbock, TX, USA
Karin Sauer Binghamton University Binghamton, NY,
USA
Pradeep Singh University of Washington Seattle, WA, USA
Phil Stewart Center for Bioﬁlm Engineering Bozeman, MT, USA
Paul Stoodley The Ohio State University, and National
Bioﬁlms Innovation Centre (NBIC),
University of Southampton
Columbus, OH, USA
Jeremy Webb National Bioﬁlms Innovation Centre
(NBIC), University of Southampton
Southampton, UK
Marvin
Whiteley
Georgia Institute of Technology Atlanta, GA, USA
Craig Williams University of West Scotland Paisley, UK
Dan Wozniak The Ohio State University Columbus, OH, USA
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Rolighed Thomsen (all involved in an informal ‘pre-meeting’ on 9
October 2018, in Washington DC, during the American Society for
Microbiology (ASM) Bioﬁlm Conference) were asked to each propose up
to six names, and all these people were pre-invited. Ultimately 29 re-
searchers from Portugal, USA, Denmark, Belgium, The Netherlands, UK,
and Australia were present (Table 1, Fig. 1).
To allow maximal input and involvement from all participants, the
‘2019 Bioﬁlm Bash’ was organized as a series of small-group brain-
storming sessions during which six questions were addressed. There were
no research presentations. These six questions were proposed by the
organizing committee but were ﬁne-tuned based on the input from the
majority of participants. Each question/topic was discussed by at least
four groups of four to six participants. In addition, to maintain the dy-
namics, groups were re-organized after every session to mix participants.
In every group a person was designated as discussion leader; this dis-
cussion leader was also responsible for reporting back to the entire group
during two plenary sessions. The outcome of these discussions is sum-
marized below.
Question 1. What will be the technologies of the future in bioﬁlm
research? Which are the developing technologies in this ﬁeld and
what technologies from outside the bioﬁlm ﬁeld could have a major2added value? How can we ensure that methods commonly used in
environmental research ﬁnd their way to clinical research and vice
versa?
The three main themes that emerged were the need to incorporate
techniques which can a) combine microscopic imaging with label free
chemical proﬁling, b) sense the bioﬁlm environment and c) process large
and complex data sets (such as omics data) with machine learning and
artiﬁcial intelligence to reveal patterns in multi-scalar relationships and
interactions between the bioﬁlm and its environment.
Bioﬁlm imaging. Imaging has been the mainstay of bioﬁlm research
and provided the ﬁrst direct proof of these communities on surfaces in
the early 1980s [1,2]. Initially scanning electron microscopy (SEM) was
used to provide high resolution images of the surfaces and transmission
electron microscopy (TEM) was required to resolve the ultrastructure
between the cells and the EPS (extracellular polymeric substance) but
these techniques require dehydration and labelling of speciﬁc compo-
nents is difﬁcult. Bioﬁlm imaging was revolutionized in the early 1990’s
by confocal microscopy which allowed live cell imaging in 3D in real
time [3,4]. However for most purposes labelling is limited to a few
compounds and the visualization of individual EPS polymers and other
components such as vesicles and determining how they structurally
interact among themselves and with the bacterial cells is beyond the limit
of resolution of this technology. Super high resolution (beyond the
diffraction limit of light) live cell imaging is now becoming increasingly
available with resolutions from 100 nm to 20 nm (in the XY plane), which
will allow us to probe these interactions [5]. Another exciting area is that
of label free imaging techniques such as Coherent Anti-Stokes Raman
Spectroscopy (CARS), which can be coupled with confocal microscopy or
matrix-assisted laser desorption ionization mass spectrometry (MAL-
DI-MS) and other MS imaging techniques to provide high resolution
chemical mapping of a specimen [6]. Imaging the EPS has been difﬁcult
not only due to limitations in microscope resolution but also because
there are no universal stains and so only targeted components can be
detected. Chemical imaging has great potential to investigate EPS
chemistry and can also be used to identify components such as antibiotics
or signals within bioﬁlms. There was some discussion on the need for
more sophisticated image analysis techniques for quantifying bioﬁlms,
which are less subjective than those used today. They largely rely on
semi-subjective thresholding and are also limited by the stains and
concentrations that the microscope can detect [7].
Sensors. Monitoring heterogeneity in the bioﬁlm microenvironment
can sometimes be achieved with speciﬁc stains. However, in many cases,
particularly in the presence of dissolved components such as nutrients or
metabolites, there are no stains available or the time scale is too slow. In
addition, direct microscopic examination might not be feasible outside
the lab (i.e. in situ such as in a wound or an industrial pipeline). Currently
microelectrodes and planar optodes can be used but these can be ﬁddly
and require direct access and sophisticated equipment thus they are most
used in the controlled environment of the laboratory. Nanobots and
nanorobotics is an area that is being developed in the ﬁeld of medicine to
send wireless signals to report on the local environment [8]. It was dis-
cussed that such technology would have great application in basic and
applied bioﬁlm research.
Artiﬁcial intelligence (AI)/machine learning (ML). We are
currently living in the age of ‘omics’, and although various ‘omics’ ap-
proaches are being applied to bioﬁlm communities, relating these large
and usually complex data sets to bioﬁlm function still often relies on
manually cherry picking a handful of familiar or likely candidate genes or
proteins, or using principal component analysis to differentiate between
overall patterns. We are still playing catch-up with providing the infra-
structure for interpreting such data sets and bioinformaticians are still in
high demand. It was predicted that AI/ML will develop in a similar way
and offer great potential in recognizing complex patterns in bioﬁlm data
sets (see for example reference [9]), integrating disparate data sets such
as 4D imaging data with multidimensional chemical data and ‘omics’
Fig. 1. Selection of pictures taken during the 2019 Bioﬁlm Bash. Top: plenary session inside the Ponderosa Lodge. Middle: Group picture with all participants in
front of Beaver Creek Lodge. Bottom left: Dinner on the ﬁrst night. Bottom right: discussions on the meadow.
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Others. In addition, many other bioﬁlm related techniques were
brought up including mechanical and rheological testing, ﬂow cytom-
etry, cryo-EM and more sophisticated computational modeling software
for integrating bioﬁlm processes with ﬂuids interactions. Some tech-
niques such as microﬂuidic platforms for high throughput experiments
and the integration of multi-scalar correlative imaging techniques, i.e.
Confocal Raman Microspectroscopy (alone or combined with stable
isotopic probing) [10], live cell imaging, small animal imaging with in
vivo imaging systems (IVIS) [11] and medical imaging techniques such as3Micro Computed Tomography (micro-CT) [12] or Magnetic Resonance
Imaging (MRI) [13] with resolutions ranging from the sub-cellular level
to the system level, are clearly promising but were not discussed in detail.
In the medical ﬁeld, medical imaging techniques which could show the
location of bioﬁlm pre- or intra-operatively would present a major
breakthrough for surgical management as well as allowing the progress
of treatments to be tracked as they are for tumor treatments. Currently
there are no bioﬁlm speciﬁc probes and the spatial resolution of medical
imaging modalities is not sufﬁcient.
Question 2. What innovative approaches to tackle unwanted
T. Coenye et al. Bioﬁlm 2 (2020) 100012bioﬁlms are needed? What can be expected from them?
The discussion focused primarily on non-antibiotic or antibiotic
adjuvant prevention and treatment strategies. These included tar-
geting the EPS matrix to break up the bioﬁlm either enzymatically or
through activating natural dispersion mechanisms [14], adding ‘poten-
tiators’ such as metabolites or nutrients which may activate persister and
stationary cells, rendering them susceptible to antibiotics [15,16], and
vaccines against bioﬁlm speciﬁc antigens [17]. Based on developments in
tumor cancer medicine, a suggestion was to use immunomodulation
therapy to disrupt the pathogenic microenvironment. It was suggested
that a solution for prevention was a surface that was inherently repulsive
to bacteria, yet was biocompatible in the clinical setting and mechani-
cally functional in engineered systems. However, as bacteria are not al-
ways attached to the surface of the implant but maybe present as
aggregates close to the surface, this may not be the perfect solution and
more studies are needed to address this. There are interesting de-
velopments in biomimicry approaches based largely on physical
patterning [18], although these tend to be expensive and there are
questions on whether patterning alone can fully explain the biological
function.
In addition to discussing novel therapies it was recognized that we
are still lacking a basic understanding of how antibiotics interact
with bioﬁlms. It is well established that cells in bioﬁlms are orders of
magnitude less sensitive to antibiotics and antimicrobial agents than
rapidly growing planktonic and early solid agar plate cultures. These data
are largely based on 24 h exposure times or less. For medical bioﬁlms
anecdotal clinical evidence suggests that bioﬁlms can survive long term
exposure to systemic antibiotics but in this case the concentration is
limited by the threshold of the therapeutic window, beyond which
toxicity is a concern. Basic research is needed to deﬁne the pharmaco-
kinetics with respect to high concentrations, which might be achieved
through local targeted delivery and over longer time scales. Another
important factor is to determine how the age of the bioﬁlm inﬂuences
susceptibility and how translational in vitro tests are to the real world
environment. The need for better models was discussed in more depth in
Question 3 (see below).
Along the same lines, the question was asked with any therapeutic
how low is low enough? It is not clear how many percent or log re-
ductions in bioﬁlm bacteria is enough, or how the absolute magnitude of
numbers which might remain, relate to clinical or industrial relevance.
Each system will have a speciﬁc tolerance and in some cases (such as
certain infections) complete eradication is required (according to con-
ventional thinking), whereas in some industrial systems (e.g. ship hull
fouling) a limited amount of bioﬁlm may be tolerated as long as it does
not cause negative effects (e.g. drag) beyond a critical operational level.
Interestingly, there was some discussion of whether the body could
tolerate a certain amount of pathogenic bioﬁlm bacteria and if thera-
peutics might still have utility if they keep the bioﬁlm in check, such as is
the case with routine oral hygiene or the use of suppressive antibiotic
therapy in patients, where surgery is contraindicated and the infecting
bacteria are susceptible to well-tolerated antibiotics.
A different approach to control medical bioﬁlms was to use ap-
proaches to reduce bacterial adhesion and bioﬁlm build up that are
commonly used in the natural environment and in industry. In pipelines
for example, dead ends where water stagnates, lags, sudden expansions
and contractions, sharp bends and surface protrusions are reduced, since
it is known that turbulent eddies associated with these features can trap
and promote bacterial attachment to surfaces. Eddies and back current
locations might furthermore form protective niches. A similar phenom-
enon occurs in infective endocarditis, where damage to the heart valve
allows bacteria to accumulate and proliferate in bioﬁlm vegetations [19].
Thus some of these design concepts, along with the use of materials that
can be more easily cleaned, might be applied to medical devices and the
hospital environment as infection control measures.
Probiotic approaches were also discussed. The use of probiotics is4now accepted with respect to gut microbiology but increasingly there is
discussion among surgeons, at least in orthopedics, that probiotics might
be used to prevent or manage deep surgical site infections. A few years
ago discussion of introducing bacteria to a deep tissue site would have
been unthinkable; now there is discussion of native joint microbiomes
[20,21] and the role of a healthy lung microbiome in infectious diseases
[22,23], opening up the door to thinking about novel therapeutics.
Question 3. How good are our experimental models? There is no
framework for bioﬁlm model evaluation in regard to how well it
recapitulates the natural environment it is meant to mimic. How
can we approach this question as a ﬁeld?
Models are essential to science and a variety of models are used in
bioﬁlm science ranging from simple in vitro models to more complex
invertebrate and vertebrate in vivo models [24,25]. The discussion
showed that there is a lack of standardization for experimental pro-
tocols and data analysis (see also below, Question 5). A publicly acces-
sible database hosting currently-used methods with protocols and
standards was proposed. This would be followed up by workshops at
general and more speciﬁc conferences and meetings during, which
(starting) bioﬁlm researchers could be trained in these methods. The
workshops would utilize material from the database and over time this
repository could become interactive. To make it easier to perform com-
parable experiments with selected models, it was suggested that lists of
preferred vendors would also be present in the database.
An important part of the discussion was related to “How do you
select an appropriate model?” It was suggested to develop a Decision
Tree for model selection that would include criteria for choice of models
as well as parameters that should be discussed during the experimental
phase and subsequently for data analyses. This would make it possible to
compare and evaluate results from similar models but from different
research groups. It was also suggested to develop a list of parameters that
should be included in manuscripts and proposals to ensure a more
informed and fair evaluation. It was discussed what would be sufﬁcient
and what will be necessary if guidelines would be developed and
enforced. When is a simple model sufﬁcient to answer the speciﬁc
research question, when should one move to a more complex model and
which types of parameters should be evaluated at each step? It was also
discussed how it can be ensured that researchers in more resource limited
settings (such as many undergraduate colleges and/or less resource rich
countries) could still be included if such guidelines were implemented.
An important aspect of model selection is to ask the right question before
making a decision about a model. In this consideration, the presence of
spatial and physiological heterogeneity needs to be accounted for.
The in situ relevance of the bioﬁlm model must also be evaluated
prior to selection, for example, prior to using a particular model, it
should be evaluated whether the inoculum, the ﬂow regime (if any) and
the surfaces/interfaces are matching the environment in the system that
is being modelled. The key drivers and parameters in the system and
environment must be identiﬁed to obtain in situ relevance. Tools should
be developed that can be used for evaluation of how the model and re-
sults can be transferred to practice and the practitioners (including cli-
nicians and engineers) should be involved in evaluation of the model to
ensure in situ relevance. Subsequently validation studies should be per-
formed (e.g. can a toilet bowl as a system be modelled in a Rotating Disk
Bioﬁlm Reactor?). The host response is also an important factor for
consideration of medical/clinical bioﬁlm models. An alternative to con-
ventional vertebrate models (mouse, rat, rabbit) are zebraﬁsh, and
invertebrate models such as Galleria mellonella or Caenorhabditis elegans
in cases where only the innate immune response is investigated [26].
Organ-on-a-chip options are increasingly being applied and beneﬁts from
the opportunities of 3D-printing and micro-hydraulic systems [27].
A discussion point was raised thatmore knowledge is needed about
the environment that is being investigated prior to the selection of a
model, since the environment often determines the organization of a
bioﬁlm. This will enhance knowledge about complexity while
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ﬁnances for repeated experiments. Also, while bad models do not exist, a
particular model can be poorly suited for answering a particular research
question and/or the interpretation of the obtained data can be bad.
Appropriate quality assurance (QA)/quality control (QC) procedures
must be in place as with all experiments and must include the quality of
the microbial inoculum as well as the rest of the model system. This will
ensure a higher degree of reproducibility. The details of the applied
methods must be outlined as a part of the QA/QC. The need to develop
relevant models for polymicrobial interactions such as infections as well
as environmental systems and many industrial problems was raised.
Stable and maybe even self-sustaining model systems are also needed.
The complexity of existing in vitro and in vivo models was discussed. Can
we -based on existing data-evaluate how good these models are? Better
approaches for evaluation of bioﬁlm models must be developed so they
accurately recapitulate the in vivo setting. Is it necessary to apply tran-
scriptomic, proteomic and/or phylogenetic techniques to document that
the applied model is accurate and can this be utilized in complex envi-
ronments? Bioﬁlm communities per deﬁnition are complex and hetero-
geneous and we need to ensure that the complexity is modelled
appropriately. However, it is currently unclear whether all systems can
be modelled. Computer modeling can potentially solve some of the gaps
that arise from experimental approaches.
Finally, there was interest in identifying a medium, where negative
data can be published, since these are often showing the limitations and
negative sides of models that are otherwise neglected.
Question 4. How can we make other stakeholders (e.g. medical
doctors, engineers, other professionals) aware that bioﬁlms are
important? What can we do to make sure that the bioﬁlm concept is
actually included in curricula and standardized tests? Can some-
thing like the bioﬁlm ‘hypertextbook’ developed at the Center for
Bioﬁlm Engineering (CBE) play a role in this? What about devel-
oping workshops that can ‘travel’ to the different bioﬁlm confer-
ences and be renewed as needed?
Increased visibility to ‘bioﬁlm’ as an integrated part of other sci-
entiﬁc ﬁelds was requested. This can be done by publishing reviews in
relevant journals as well as by interacting with the lay press (e.g.
informing newspapers and local media about new discoveries and overall
information about bioﬁlms). Increased use of social media as a platform
should also be considered to reach younger demographics. Informative
YouTube videos and TED-style talks by high-proﬁle scientists and other
thought leaders could also be a part of ‘marketing’ the bioﬁlm concept.
We can increase the visibility of ‘bioﬁlm’ by always including it as a
keyword, use social media (Twitter, ResearchGate, LinkedIn etc.) to
highlight bioﬁlm-related publications but also by writing position papers
to be published in journals that typically do not have a bioﬁlm focus.
Publication of case reports involving bioﬁlms will increase the awareness
about bioﬁlms in the clinical and industrial ﬁelds and can be delivered in
a way that will promote appreciation of bioﬁlms when they occur in the
these settings. Furthermore, a correction of decades of misconception in
the ﬁeld that a bioﬁlm is a surface-attached mushroom-shaped structure,
must take place. This will likely increase the general awareness, since
people will be able to associate and identify their ﬁndings as a bioﬁlm
even though it is not a mushroom-like structure. For the bioﬁlm message
to be received, the message must be deﬁned and reﬁned so it will hit the
target audience. The American Cancer Society has been very successful in
delivering their message (supported by effective fundraising) and it was
suggested that this could serve as a model. In this way bioﬁlms can be
linked to important societal issues such as antimicrobial resistance, mi-
crobial corrosion and chronic infectious diseases, but also to the positive
aspects related to for instance wastewater treatment, food production
and bioremediation. An important aspect for this part to move forward is
to identify existing data on the burden and beneﬁts of bioﬁlms, respec-
tively. It is also imperative to link bioﬁlm to other recognized concepts
such as cancer, global warming (including coral bleaching), and food5production, and to estimate the ﬁnancial and human global burden.
Primary and secondary education (K-12 in the US) as well as
education at the university level are important gateways to increasing
the awareness and knowledge about bioﬁlms. More focus on providing
information and materials for teachers at all levels will increase the
general awareness. This could be done by providing examples of harmful
and beneﬁcial bioﬁlms for different levels that educators can include
directly in their lesson plans and in the classroom. Experimental bioﬁlm
instruction can also be facilitated by examples and protocols that high
school and university students can beneﬁt from. Establishment of a
database with protocols and vendor information (cfr. Question 3) would
also be a part of improved outreach to educators. Wikipedia and other
links could add to the knowledgebase for middle and high school stu-
dents. Resources already exist such as ‘Evolving STEM’ (https://evolving
stem.org/) that can be included right away.
Continuing education of professionals at major conferences and
other venues will also be an important aspect. Several medical organi-
zations offer courses, workshops etc. to obtain CME (Continuing Medical
Education) and CE (Continuing Education) credits. The topic of bioﬁlm
should become a part of CME/CE and other types of continued education
for other organizations. To get bioﬁlm to be a part of CME/CE, increased
impact of bioﬁlm must be pushed at the general microbiology meetings
that take place at an annual basis such as ASMMicrobe, the Federation of
European Microbiological Societies (FEMS) Congress of European
Microbiology, The Microbiology Society Annual Meeting (UK) and the
European Congress of Clinical Microbiology & Infectious Diseases
(ECCMID). This could also provide an avenue for making ‘bioﬁlm’ a topic
for the Medical Board Exam, Dental Board Exam, and the Fundamentals
of Engineering Exam (the Engineering Board exam). The push for in-
clusion on the Board Exams has a straightforward path in the US. How-
ever, in Europe and globally, this must be individually targeted for each
country.
Question 5. Standardization/databases/data sharing. Should
there be a bioﬁlm database in which large datasets relevant to the
ﬁeld are uploaded to prevent the need for each group to scour
existing databases. If so, where should it be maintained and who
can curate it? Maybe crowdsource? This is an issue for labs that
don’t have the expertise to analyze large datasets and for labs that
focus on large datasets.
Should we standardize our models? When is standardization
required? The question about ‘standardization’ is not new (see also
Question 3, above), but remains relevant in the bioﬁlm research ﬁeld and
is frequently the subject of debate. Standardization of methods is often
driven by regulatory authorities (e.g. the US Food and Drug Adminis-
tration [FDA], the US Environmental Protection Agency [EPA], and the
European Medicines Agency [EMA]) and industry, and this is also the
case in the bioﬁlm ﬁeld [28–32]. Standardmethods allow for comparison
across treatments and devices, enable regulatory agencies to make
informed decisions, and provide insights into the Type 1 and Type 2 error
rates that can be expected, when the treatment or device is tested in a
clinical or industrial trial. Standard methods used for applications
beyond their intended ‘signiﬁcance and use’ may provide misleading
results, but the error is the result of misuse of the method, not due to the
inadequacies of the standardization. Finally, standard methods are living
documents that require constant review and updating. As science and
technology evolve, so should the standard methods. Standardized
methods can also play an important role in increasing our understanding
of the basic biology of bioﬁlms, including insights into the mechanisms
involved in bioﬁlm tolerance. Comparison of results obtained in absence
of some form of standardization is at best difﬁcult [33]. Standardized
methods are important tools for screening of large libraries for potential
compounds with anti-bioﬁlm activity [32]. However, regardless of
standardization, in vitro bioﬁlm susceptibility tests will frequently (but
not always, [34–36]) yield results that are poorly representative of the
actual activity of the antibiotic against the bioﬁlm in vivo, because of
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important point, because it illustrates that even the best in vitro model
does not fully mimic the in vivo situation. Progress has been made in
developing laboratory bioﬁlm models that are more representative of the
situation in a patient (e.g. in the context of chronic wound infections and
CF) [37,38] and industrial environments [39], but studies establishing
the validity of these models are still largely lacking. Finally, in some
contexts it may be more readily achievable and useful to standardize
speciﬁc key parts of workﬂows and procedures, rather than the entire
method. For example, it may be difﬁcult to standardize the entire
workﬂow of bioﬁlm formation, antimicrobial treatment and crystal violet
staining in a 96-well microtiter plate, but the staining procedure as such
could be standardized.
Do we need bioﬁlm-speciﬁc repositories? What about sharing
and re-use of data? Standardization would also improve the content of
databases, and the other way around, databases can promote the stan-
dardization efforts. Databases in the context of bioﬁlm research could
refer to physical databases for microbial strains, and to computer data-
bases for a wide range of different data types (images, genomics, tran-
scriptomics etc.).
For the deposit of (mutant) strains no additional initiatives are
necessary. Strains can be deposited in a number of international culture
collections (including ATCC in the US and BCCM/LMG Bacteria Collec-
tion in Belgium). This deposit guarantees that a particular strain is not
lost and allows other researchers to easily obtain it. In addition, special
panels of microorganisms can be assembled and deposited in these col-
lections. A recent example of this includes the international Pseudomonas
aeruginosa reference panel [40]. The deposition of (sets of) strains in
international culture collection will allow researchers from different
laboratories to work on the same strain, which will facilitate comparison
of results obtained with different experimental approaches in different
laboratories. Making sure that biological material included in published
bioﬁlm studies is available to other researchers is a shared responsibility
of authors and journals/publishers; with the need for the latter to be
stricter about this.
There is less consensus about the deposition of data, although overall
the feeling was that one or more repositories dedicated to bioﬁlm data
could be useful. As an example, the WormBase repository for data con-
cerning Caenorhabditis elegans and related organisms was mentioned
[41]. However, the added value of depositing bioﬁlm-derived ‘omics’
data in a second database (besides e.g. GenBank and ArrayExpress) was
questioned. The experience with the BiofOmics web platform aimed at
the systematic and large-scale compilation, processing and analysis of
bioﬁlm data from high-throughput experiments [31] shows that it is
difﬁcult to convince researchers to deposit their data and the curation of
such database(s) is time-consuming. A possible solution to that is
crowdsourcing of curation, but that solution carries the risk of intro-
ducing bias and variability. In addition, the main goal of data deposition
is re-use of data and this has several implications. Besides the issue of
standardization outlined above, there is also the issue concerning met-
adata – i.e. what information about a dataset is required before data can
be re-used? In 2014, standards for reporting experiments and data on
bioﬁlms were published (minimum information about a bioﬁlm experi-
ment, MIABiE) [30] but the uptake of these guidelines has been slow,
both on the side of the scientiﬁc community (i.e. bioﬁlm researchers) and
on the side of journals/publishers. Regardless, there seems to be a
consensus that more efforts are needed to make raw data and the asso-
ciated relevant metadata available as soon as possible, at the latest when
the research results are published. This is a shared responsibility of au-
thors and editors. A ﬁnal added value of a bioﬁlm data repository is that it
would force researchers to upload their data and metadata in a certain
way, opening up the possibilities of performing meta-analyses on these
data.
Can we provide guidance to (starting) bioﬁlm researchers?With
the ever-growing number of bioﬁlm-related papers published and the
wide range of different methods available, it is not easy for researchers6new in the ﬁeld (or new to a particular subdiscipline in the ﬁeld) to
choose the most appropriate model system (see also Question 3). While
there are several review papers on various aspects of bioﬁlm model
systems and bioﬁlm methods in general [24,25,38,42], it seems that this
information is not easily available for researchers. An example of this is
the widespread use of crystal violet staining. While this can be a valuable
tool, it is often used in experiments that would be better served by other
output parameters. In addition, some guidance towards data interpreta-
tion may also be needed (e.g. how much bioﬁlm reduction is needed in a
particular model before considering it biologically meaningful?). A
comprehensive decision making algorithm (cfr. Decision Tree for model
selection in Question 3, above) for choosing the most optimal approach
for a particular bioﬁlm experiment would be considered useful and
detailed information about bioﬁlm methods (principles, protocols, ex-
amples of studies using these protocols) should ideally be available on-
line, e.g. as part of the ‘Bioﬁlms: The Hypertextbook’ website (http://
www.hypertextbookshop.com/bioﬁlmbook/v004/r003/) maintained
by the Center for Bioﬁlm Engineering.
Question 6. What do we see in the future of the ﬁeld in terms of
journals, conferences, organization, training schools? Is there a
way to (re-)unite the ﬁeld in terms of conferences - is this necessary
or are we happy the way it is? What model(s) do we see in the future
for bioﬁlm research? Is there need for more and/or larger (virtual)
centers like the CBE (Center for Bioﬁlm Engineering), NBIC (Na-
tional Bioﬁlms Innovation Centre) and SCELSE (Singapore Centre
for Environmental Life Sciences Engineering)? Is there a need for an
independent bioﬁlm society focusing on bioﬁlms in health, envi-
ronment and energy?
Although bioﬁlms impact all aspects of life and biological sciences, it
is viewed as a separate ﬁeld. Is this due to historical reasons, with
bacteriology historically involving shaken cultures andmostly planktonic
bacteria or is it because we as a ﬁeld have isolated ourselves on purpose
(e.g. by organizing dedicated bioﬁlm conferences)? Bioﬁlms are likely
involved in most (if not all) aspects of microbiology, but this is often
overlooked.
Organization within the ﬁeld and outreach. One of the key points
of the ‘Bioﬁlm Bash’ was to discuss whether an International Bioﬁlm
Society should or could be formed. This was welcomed as an intriguing
idea, and would give visibility to the ﬁeld, but there were also many
questions about its goals, the practical organization and ﬁnancial aspects.
Several societies for microbiology already exist and it was argued that
forming an International Bioﬁlm Society would tap into the energy and
passion that people have for the ﬁeld and may dilute and ﬁnancially
damage the existing societies. The general feeling was that it would be
better to use the existing microbiology societies (including ASM, FEMS
and the European Society for Clinical Microbiology and Infectious Dis-
eases [ESCMID]) to ‘push the bioﬁlm agenda’ while at the same time
opening up the ﬁeld to others (including bioengineers, mathematicians
etc.). Successful global outreach and public engagement will likely
require more educational material, position papers, and text books (see
also Question 4). A list of future stakeholders include -but is not limited
too-schools, universities, industry, regulatory agencies and governments.
Conferences. Another point for discussion was bioﬁlm conferences:
do we need more or less? There was a general consensus that we should
not have more conferences on bioﬁlms, the ﬁeld is saturated. Rather we
should aim to have more joint meetings as too many meetings dilute the
impact and attendance. A preferred scenario is to have one bioﬁlm
conference every year with large joint conferences every 3rd or 6th year.
It has been proposed before to combine the different bioﬁlms conferences
but so far attempts have been unsuccessful. However maybe in the light
of the ‘Bioﬁlms Bash’, we could approach the different bioﬁlm confer-
ence organizers to discuss a united approach. The consensus was that we
need to rely more on existing microbiological societies and their (gen-
eral) meetings to organize these conferences. It was also proposed to
setup a Gordon or Keystone conference on bioﬁlms. Strategies for future
Box 1
Action items identiﬁed during the plenary discussions.
 Techniques used to study the microenvironment of solid tumor cancers and for in situ research of microbial communities in the natural
environment have great potential for application to laboratory bioﬁlm experiments, and should be translated to other ﬁelds such as industrial,
medical or dental bioﬁlms. One way to achieve this would be for bioﬁlm researchers to attend methods intensive conferences outside the
bioﬁlm ﬁeld. The International Society for Microbial Ecology (ISME) conference was cited as an excellent example.
 A second path would be to bring in speakers from other ﬁelds to future bioﬁlm conferences whomwere developing methods in their own ﬁelds
which may be translatable.
 Workshops dedicated to speciﬁc techniques which might have bioﬁlm applications could help advance the ﬁeld.
 A better overview of what is available (worldwide) in terms of training opportunities is desirable and it needs to be explored how different
initiatives can be connected.
 A well-documented study demonstrating that a bioﬁlm speciﬁc therapeutic has clinical efﬁcacy, where conventional surgical or antibiotic
interventions had failed, would advance the medical bioﬁlm ﬁeld. If a bioﬁlm approach could be demonstrated in one type of infection, then the
doors might open to spark innovation in treating other types of bioﬁlm infections.
 In terms of surface modiﬁcations, silver alloy in the coating of a urinary catheter has demonstrated a reduction in infections [43]. However, the
mechanism of action, whether it reduced adhesion or inﬂuenced bioﬁlm development is un known. More fundamental knowledge on the mode
of action of successful surface modiﬁcations beyond silver alloys is needed.
 The lack of a deﬁnitive bioﬁlm biomarker and medical imaging modality for detecting bioﬁlms makes it difﬁcult to assess the impact of anti-
bioﬁlm therapeutics. Thus work towards a suite of bioﬁlm markers is needed.
 There is need for a position paper on the applicability and limitations of bioﬁlm and host/environmental models. Topics such as the ones listed
below could be discussed in this paper: (i) Deﬁne constraining parameters in model systems with respect to spatial and temporally relevant
scales. This in an engineering approach, where the goal is to deﬁne the principal features that we need in a model given that the complexity
prohibits all variables. (ii) Development of enhanced tools for accurate evaluation of the applied model. (iii) Application of computer models to
aid in evaluation. (iv) Assess the utility of artiﬁcial intelligence in bioﬁlm control evaluation.
 Wikipedia is often the ﬁrst source of information (lay) people ﬁnd, so we need to make sure the ‘Bioﬁlm’Wikipedia page is current and updated.
 To deliver a clear and consistent message about what a bioﬁlm is, a set of slides (1–3 slides) will be developed that can be shared by all
interested.
 There is an urgent need to bring a clear message to stakeholders about the importance of bioﬁlms. No reliable estimates of the overall burden of
bioﬁlm infections have been published since 2010 [44] and an updated estimate of the human, ﬁnancial, and social burden of clinical and
industrial bioﬁlms is needed. What are the beneﬁts of bioﬁlms in certain systems? What costs are associated with bioﬁlm-related fouling?
Different target audiences will need different clear messages. An essential aspect of this is bringing the bioﬁlm concept to the attention of
funding organizations. Antimicrobial resistance and microbiome management are now accepted areas of concern and targets for therapeutics
but we need to better incorporate the concept of bioﬁlms into these discussions to highlight issues with controlling bioﬁlms. In parallel, the
beneﬁts of bioﬁlms should also be estimated and delivered to stakeholders interested in promoting bioﬁlm.
 Development of a Bioﬁlm Text Book could help reach a wider audience. The current version hosted by the CBE could be further developed.
 We need to ‘push’ the bioﬁlm concept with scientiﬁc and professional organizations so it is included in recommended training programs,
continued education activities and curricula.
 There are several misconceptions in the ﬁeld, including that bioﬁlms always take the form of mushroom-shaped structures, that the process of
bioﬁlm formation follows a ﬁxed developmental cycle, and that all bioﬁlms are surface-attached. These misconceptions need to be corrected
and the message delivered to a wide target audience.
 We need to discuss to what extent we expect bioﬁlm experiments to be standardized and if so in what aspects of the workﬂow standardization is
most important. Guidelines that reﬂect this should be developed. ‘Minimum information’ guidelines [30] can support researchers, reviewers
and editors to determine whether the information required to successfully reproduce an experiment is available. In addition, we need to make
sure these guidelines are disseminated widely to ensure that they are adopted by all stakeholders.
 There was a consensus that there is currently no need for a separate bioﬁlm society. However, if we want to further integrate the ﬁeld at an
international level, we need to explore funding opportunities and talk to funding organizations and program ofﬁcers.
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ﬁeld: we need people to understand that bioﬁlms are not a special thing
but rather the common mode of growth of microorganisms!
Journals. As for bioﬁlm speciﬁc journals, it was thought that the
market is already saturated. With the new journal ‘Bioﬁlm’ we have
enough speciﬁc journals and bioﬁlm research can also be published in the
existing more general journals.
Training schools and courses. It was discussed how we can educate
researchers about bioﬁlm and use existing knowledge and resources
better. Training schools and workshops, such as Summer Schools, to
learn the basics of bioﬁlm models are still needed but it is worth inves-
tigating whether this can be organized at a larger international scale
(Woods Hole and Cold Spring Harbor course programs were mentioned
as examples) as such courses would beneﬁt from a more interdisciplinary
approach. There also seems to be a need for shorter/more dedicated
courses also offering data analysis, including statistics. Other suggestions
for workshops and short courses/training schools include image analysis,
ﬂow cells, microscopy, industrial bioﬁlms, regulatory aspects of bioﬁlms,
hands-on techniques, clinical/medical bioﬁlms, dental bioﬁlms,7environmental bioﬁlms, and bioﬁlms in engineering. These courses/
workshops could also be part of conferences as is already happening with
Eurobioﬁlms, ASM Conference on Bioﬁlms and ChinaBioﬁlms. It is pro-
posed to make a list of available hands-on courses as well as online
courses (e.g. https://bioﬁlmcourse.ku.dk/, https://www.coursera.o
rg/learn/bacterial-infections).
Networking. The bioﬁlm ﬁeld would beneﬁt from a map of available
infrastructure, resources, societies, as well as integrative conferences and
courses. Increased interdisciplinary and international networking would
also be beneﬁcial and the larger centers (e.g. NBIC, CBE, SCELSE) can and
should play a role in catalyzing these interactions. This was discussed
extensively and although the value of this (e.g. in leveraging interna-
tional funding initiatives) was clear to all, organizing this on an inter-
national level is challenging. Funding agencies that could be contacted
for this include the National Science Foundation (NSF, US), National
Institutes of Health (NIH, US) and the European Cooperation in Science
and Technology (COST) intergovernmental framework. Regardless of
which partnerships/networks will develop in the future, these should be
inclusive. We will need to act as a connected community to successfully
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Concluding statements
It is very difﬁcult to capture everything that was discussed between
29 people during two days of engaged and animated discussions.
Nevertheless, we are convinced that the most important issues are
covered in the summary above. In addition, during the plenary sessions,
several action items were identiﬁed. These are often transversal (i.e. cut
across the different questions) and are summarized in Box 1. With the
support of the wider bioﬁlm community, we will start addressing those
action items in the near future. Progress updates will be presented at the
various bioﬁlm conferences and other meetings as well as in writing.
Author contribution
Considering the special nature of this paper and the author list, we
prefer not to include an Author Contribution Statement, as we feel that in
this case this had no added value.
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